Table 1.

Association of C12orf59 expression with patient’s clinicopathological features in GC

Variables	Case	Training cohort		P-value	Case	Validation cohort		P-value
		Low expression	High expression			Low expression	High expression
Age		102	68			79	53
≤60a	100	65 (50.9%)	35 (49.1%)		78	51 (54.5%)	27 (45.5%)
>60	70	37 (58.1%)	33 (41.9%)	0.112	54	28 (53.5%)	26 (46.5%)	0.119
Gender
Male	109	64 (50.0%)	45 (50.0%)		88	51 (50.0%)	37 (50.0%)
Female	61	38 (63.3%)	23 (36.7%)	0.648	44	28 (63.3%)	16 (36.7%)	0.53
Tumor grade
G1	56	39 (42.1%)	17 (57.8%)		38	23 (65.8%)	15 (34.2%)
G2 + 3	114	63 (61.7%)	51 (38.3%)	0.072	94	56 (46.7%)	38 (53.3%)	0.92
Tumor size(cm)
≤ 5b	91	59 (51.0%)	32 (49.0%)		97	62 (53.1%)	35 (46.9%)
>5	79	43 (57.1%)	36 (42.9%)	0.167	35	17 (55.1%)	18 (44.9%)	0.112
T status
T1/2	37	25 (54.2%)	12 (45.8%)		44	31 (50.0%)	13 (50.0%)
T3/4	133	77 (54.1%)	56 (45.9%)	0.288	88	48 (55.4%)	40 (44.6%)	0.079
N status
N0	58	43 (34.5%)	15 (65.5%)		61	43 (72.4%)	18 (27.6%)
N1/2	112	59 (62.3%)	53 (37.7%)	0.007*	71	36 (46.4%)	35 (53.6%)	0.021*
Clinical stage
I + II	69	50 (37.8%)	19 (62.2%)		70	49 (67.6%)	21 (32.4%)
III	101	52 (63.9%)	49 (36.1%)	0.006*	62	30 (45.9%)	32 (54.1%)	0.011*

a Mean age. b Mean tumor size. *Statistically significant difference